Home
About
Overview
Sharing Data
ORCID
Help
History (24)
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
Crystallization and preliminary X-ray study of the edema factor exotoxin adenylyl cyclase domain from Bacillus anthracis in the presence of its activator, calmodulin.
Spontaneous restoration of transplantation tolerance after acute rejection.
Bar the windows but open the door to randomization.
See All 24 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Bar the windows but open the door to randomization.
Bar the windows but open the door to randomization. J Clin Oncol. 2010 Jul 01; 28(19):3104-6.
View in:
PubMed
subject areas
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Burkitt Lymphoma
Carcinoma, Non-Small-Cell Lung
Humans
Indazoles
Lung Neoplasms
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Neoplasms
Pyrimidines
Randomized Controlled Trials as Topic
Rituximab
Sulfonamides
Treatment Outcome
authors with profiles
Mark Ratain